Source comparison
MOTS-C Versus Other Mitochondrial-Targeting Peptides
MOTS-C comparative studies also benchmark the compound against structurally similar mitochondrial-derived peptides. Primarily humanin and SHLP2 (small humanin-like peptide 2). All three are encoded by mitochondrial DNA rather than nuclear DNA, and all three ex
This comparison does not assign a generated winner or score.
- MOTS-C comparative studies also benchmark the compound against structurally similar mitochondrial-derived peptides. Primarily humanin and SHLP2 (small humanin-like peptide 2). All three are encoded by mitochondrial DNA rather than nuclear DNA, and all three exhibit cytoprotective and metabolic effects. A 2022 comparative trial in Cell Metabolism administered MOTS-C, humanin, or vehicle to diet-induced obese mice for 8 weeks. MOTS-C reduced body weight by 18%, humanin by 11%, and vehicle by 2%. Both peptides improved glucose tolerance, but MOTS-C produced significantly greater reductions in fasting blood glucose (−34% versus −19% for humanin) and greater improvements in insulin sensitivity during glucose tolerance testing.
- The mechanistic distinction: humanin primarily exerts anti-apoptotic effects. It protects cells from stress-induced death and improves mitochondrial membrane stability. MOTS-C directly regulates metabolic gene expression by translocating to the nucleus and binding to specific promoter regions that control glucose and lipid metabolism. Humanin is protective; MOTS-C is metabolically active. That's why MOTS-C comparative studies consistently show greater metabolic remodelling. Weight loss, insulin sensitivity, fat oxidation. While humanin shows greater neuroprotective and cardioprotective effects in ischemia models.
- Another comparison point: MOTS-C versus SS-31 (Elamipretide), a synthetic mitochondria-targeting peptide that stabilises cardiolipin and improves electron transport chain efficiency. SS-31 enhances ATP production and reduces oxidative stress but doesn't directly activate AMPK or alter substrate metabolism the way MOTS-C does. SS-31 trials focus on heart failure, mitochondrial myopathies, and neurodegenerative conditions. Populations where energy production is impaired. MOTS-C trials focus on metabolic syndrome, obesity, and insulin resistance. Populations where substrate utilisation is dysregulated. Different peptides, different clinical targets.